3uns: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor== | ==Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor== | ||
<StructureSection load='3uns' size='340' side='right' caption='[[3uns]], [[Resolution|resolution]] 1.80Å' scene=''> | <StructureSection load='3uns' size='340' side='right' caption='[[3uns]], [[Resolution|resolution]] 1.80Å' scene=''> | ||
| Line 6: | Line 7: | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1v2k|1v2k]], [[3unq|3unq]], [[3unp|3unp]], [[3upe|3upe]], [[3uqo|3uqo]], [[3uqv|3uqv]], [[3uqz|3uqz]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1v2k|1v2k]], [[3unq|3unq]], [[3unp|3unp]], [[3upe|3upe]], [[3uqo|3uqo]], [[3uqv|3uqv]], [[3uqz|3uqz]]</td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Trypsin Trypsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.4 3.4.21.4] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Trypsin Trypsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.4 3.4.21.4] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3uns FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3uns OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3uns RCSB], [http://www.ebi.ac.uk/pdbsum/3uns PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3uns FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3uns OCA], [http://pdbe.org/3uns PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3uns RCSB], [http://www.ebi.ac.uk/pdbsum/3uns PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3uns ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 16: | Line 17: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 3uns" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
Revision as of 20:46, 11 August 2016
Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitorBovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor
Structural highlights
Publication Abstract from PubMedAbstract A high-resolution crystallographic structure determination of a protein-ligand complex is generally accepted as the 'gold standard' for structure-based drug design, yet the relationship between structure and affinity is neither obvious nor straightforward. Here we analyze the interactions of a series of serine proteinase inhibitors with trypsin variants onto which the ligand-binding site of factor Xa has been grafted. Despite conservative mutations of only two residues not immediately in contact with ligands (second shell residues), significant differences in the affinity profiles of the variants are observed. Structural analyses demonstrate that these are due to multiple effects, including differences in the structure of the binding site, differences in target flexibility and differences in inhibitor binding modes. The data presented here highlight the myriad competing microscopic processes that contribute to protein-ligand interactions and emphasize the difficulties in predicting affinity from structure. Correlating structure and ligand affinity in drug discovery: a cautionary tale involving second shell residues.,Tziridis A, Rauh D, Neumann P, Kolenko P, Menzel A, Brauer U, Ursel C, Steinmetzer P, Sturzebecher J, Schweinitz A, Steinmetzer T, Stubbs MT Biol Chem. 2014 Jul 1;395(7-8):891-903. doi: 10.1515/hsz-2014-0158. PMID:25003390[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||||